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Acute Transdermal Nicotine Improves Cognitive Deficits in Children,
Adolescents, and Young Adults with Attention Deficit Hyperactive
Disorder
Abstract
Background: Attention deficit hyperactive disorder (ADHD) is described as a neurobiological syndrome
affecting approximately 5% of children and adolescents as reported by the American Academy of Pediatrics in
2008. Problems in school are often a key clinical finding for children with ADHD. Children with ADHD are
associated with low academic grades and poor academic performances. Current pharmacological treatments,
like pychostimulants, help to decrease core behavioral symptoms and increase academic productivity, but
overall performance on standardized tests are often unaffected.Previous research has shown those with
ADHD are two times more likely to smoke cigarettes and initiate cigarette smoking at an earlier age in
comparison to those without ADHD. Nicotine has proven beneficial with improvement of symptoms, moods,
and cognitive functioning in studies containing both smoking and non-smoking adults with ADHD. This
review will look at the effects of acute transdermal nicotine on cognitive functioning in children, adolescents,
and young adults with attention deficit hyperactive disorder.
Methods: An exhaustive search of available literature was performed using MEDLINE-Ovid, Web of Science,
and Google Scholar. Keywords included: nicotine patch, transdermal nicotine, attention deficit hyperactivity
disorder, ADHD, cognitive functioning, and symptom improvement. Using the GRADE criteria, all relevant
articles were assessed for quality.
Results: A total of 11 articles were screened for relevance. After this review, 2 articles met inclusion criteria.
One study showed improvements of learning problems associated with ADHD after a 7 day transdermal
nicotine application. The second study revealed improvements in impulse control and other cognitive deficits
after a 45-minute transdermal nicotine administration.
Conclusion: Based on the results and limitations of these studies further research is needed to determine the
true efficacy and safety of using transdermal nicotine to treat ADHD, but the possibility of using nicotine in
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Abstract  
Background: Attention deficit hyperactive disorder (ADHD) is described as a neurobiological 
syndrome affecting approximately 5% of children and adolescents as reported by the American 
Academy of Pediatrics in 2008. Problems in school are often a key clinical finding for children 
with ADHD. Children with ADHD are associated with low academic grades and poor academic 
performances. Current pharmacological treatments, like pychostimulants, help to decrease core 
behavioral symptoms and increase academic productivity, but overall performance on 
standardized tests are often unaffected. Previous research has shown those with ADHD are two 
times more likely to smoke cigarettes and initiate cigarette smoking at an earlier age in 
comparison to those without ADHD. Nicotine has proven beneficial with improvement of 
symptoms, moods, and cognitive functioning in studies containing both smoking and non-
smoking adults with ADHD. This review will look at the effects of acute transdermal nicotine on 
cognitive functioning in children, adolescents, and young adults with attention deficit 
hyperactive disorder. 
Methods:  An exhaustive search of available literature was performed using MEDLINE-Ovid, 
Web of Science, and Google Scholar. Keywords included: nicotine patch, transdermal nicotine, 
attention deficit hyperactivity disorder, ADHD, cognitive functioning, and symptom 
improvement. Using the GRADE criteria, all relevant articles were assessed for quality.  
Results:  A total of 11 articles were screened for relevance. After this review, 2 articles met 
inclusion criteria. One study showed improvements of learning problems associated with ADHD 
after a 7 day transdermal nicotine application. The second study revealed improvements in 
impulse control and other cognitive deficits after a 45-minute transdermal nicotine 
administration. 
Conclusion:  Based on the results and limitations of these studies further research is needed to 
determine the true efficacy and safety of using transdermal nicotine to treat ADHD, but the 
possibility of using nicotine in various treatment modalities or a nicotine agonist in the acute 
setting has potential to be a viable option in the future. 
Keywords:  Attention deficits hyperactive disorder, transdermal nicotine, cognitive problems, 
adolescents, and young adults 
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BACKGROUND 
Attention deficit hyperactive disorder (ADHD) is described as a neurobiological 
syndrome affecting approximately 5% of children and adolescents worldwide.1,2 ADHD is often 
associated with poor academic scores, increased grade retention, and low graduation rates. 
Pharmacological and behavior treatment modalities are associated with a reduction in symptoms 
and increase academic productiveness but without improvement in standardized test scores.3  
School-based problems are often a key clinical finding in initially identifying those with 
ADHD. The Diagnostic and Statistical Manual of Mental Disorders – 5th edition (DSM V) 
defines ADHD as a persistent pattern of inattention and/or hyperactivity-impulsivity occurring 
before age 12 that interferes with functioning or development in two or more settings, (eg, home, 
school, or work) that has direct negative impacts on social, academic, or occupational 
functioning.4 A tool used to assist with the diagnosis of ADHD is called the Conner’s 
Comprehensive Behavior Rating Scale. It is a list of screening questions assessing for 
deficiencies in emotion, behavior, and academics witnessed by a parent, a teacher, and the child 
him or herself.5  
Even though, the diagnosis of ADHD is based primarily on subjective behavior problems, 
cognitive problems tend to be affected as well. A meta analysis performed in 2006 showed those 
with ADHD have problems with executive functioning.6 Prominent cognitive problems tend to 
be linked to behavior inhibition, working memory, regulation of motivation, motor control, and 
sustained attention,7,8 possibility contributing to overall low academic outcomes. 
Currently approved pharmacological treatment modalities for ADHD involve 
psychostimulant medications such as methylphenidate (Ritalin), dexmethylphenidate (Focalin), 
or a combination dextroamphetamine-amphetamine (Adderall).9 These treatment options have 
demonstrated improvements in behavior deficits but acute cognitive deficits are often 
unaffected.10 Another issue with current psychostimulants is their potential addiction risk and 
cardiovascular risk.9 Therefore, careful monitoring and regular office visits are often needed to 
determine efficacy and safety. 
Previous research on ADHD has determined adolescents with ADHD are two times more 
likely to become cigarette smokers and are more likely to initiate cigarette smoking at an earlier 
age than adolescents without ADHD. Current theories suggest that cigarette smoking, 
specifically nicotine administration, is a form of self-medication and therefore a potential drug 
therapy.11,12 
Nicotine is a tertiary amine compound found naturally in tobacco. Nicotine binds to the 
nicotinic cholinergic receptors found in multiple areas of the brain, the autonomic ganglia, and 
neuromuscular junctions. When activated it stimulates a release of neurotransmitters, including 
acetylcholine, norepinephrine, dopamine, serotonin, B endorphins, and others. The nicotine 
cholinergic receptor activation in the adrenal medulla releases epinephrine and other B 
endorphins.13 A study performed on 11 adult patients with ADHD found nicotine therapies to 
have similar neurochemical effects to other stimulant-like mediations by lowering striatal 
dopamine transporters in the brain.14 Nicotine administration through cigarette smoking is known 
to increase cardiovascular risk mainly due to its stimulant like effects, but the administration of 
transdermal nicotine has not been proved to be associated with any serious or rare 
complications.13,15 
A study performed by Levin et al16 showed a subjective and clinical reduction in ADHD 
symptoms and an increase in cognitive functioning associated with a nicotine therapy in both 
smoking and non-smoking adults. Attempting to treat the symptoms at an earlier age would help 
provide an alternative treatment modality to children and adolescents with ADHD. This review 
will assess if acute transdermal nicotine treatments could potentially increase cognitive 
functioning and decrease symptoms in children, adolescents, and young adults with ADHD.  
METHODS 
An exhaustive search of available literature was performed using Medline- OVID, Web of 
Science, and Google Scholar. Keywords included in the search were nicotine patch, transdermal 
nicotine, ADHD, attention deficit hyperactivity disorder, cognitive functioning, and symptom 
improvement. The search was limited to include only studies done on humans, in the English language, 
and on children, adolescents, or young adults in the subject demographics. Other articles were assessed 
for further information. Using the GRADE criteria, all relevant articles were assessed for quality.17  
RESULTS 
A total of 11 articles were screened for relevance. After this review, 2 studies18,19 met inclusion 
criteria. Both articles were randomized control trials, in the English language, performed on humans 25 
years of age or younger. See Table 1. 
Shytle et al. 
This was a double blind, randomized controlled trial18 testing the effects of a 5 mg/16 hour daily 
transdermal nicotine patch versus a placebo patch in 10 children and adolescents between the ages of 8 
and 13 years of age, who meet the DSM IV criteria for ADHD. Potential participants currently taking 
psychoactive drugs and those with drug, alcohol, or tobacco abuse or dependence within 6 month from 
the start of the trial and were excluded. The study was performed over a 7 day period and subjects were 
instructed to apply a new transdermal patch daily. Subjects and the parents of subjects were also 
instructed to keep a diary assessing for compliance. Participants were instructed to remove the patch if 
they experienced abnormal side effects, specifically nausea or dizziness. If the patch was removed due 
to side effects, subjects were informed to apply a new patch the next day. A 48-item Conner’s Parent 
Rating Scale(CPRS) and the Clinical Global Impression (CGI) Scale were used to assess for 
symptomatological changes at baseline, day 0 and day 7.  The Conner’s Parent Rating Scale was divided 
into 6 subgroups: conduct problems, learning problems, psychosomatic, impulsivity, anxiety, and 
hyperactivity.18 
Shytle et al study found the nicotine group to be statistically significant in improvement of  
“learning problems,” a subset of an item in Conner’s Parent Rating Scale. Although the nicotine group 
showed improvements in all the other subgroups, none were found to be statistically significant. The 
Clinical Global Impression Scale assessment was inconclusive in showing any differences between the 2 
groups after a 7-day period. Along with the benefits of nicotine, the treatment group reported elevated 
levels of side effects. Eighty percent of the treatment group reported nausea and 60% reported stomach 
aches and local skin irritation associated with the transdermal nicotine administration.18 
The biggest limitation mentioned by the authors of this study was the possible compromise of 
blinding. The treatment group was noted to have high percentage of side effects, including nausea, 
stomach aches, local irritation under the patch, and dizziness. Although attempts were made to keep the 
placebo transdermal application similar in size and smell, Shytle et al was unable to predict the treatment 
groups’ side effects. With the associated side effects profile dominating the treatment group, it could 
have been easy for the researcher to determine which subjects were a part of the treatment group, thus 
compromising the overall blinding of this study.18 
Potter and Newhouse 
 This was a randomized, controlled, double blind pilot study19 comparing the effects behavior 
inhibition, delay aversion, and recognition memory after application of a 45 minute 7 mg transdermal 
nicotine patch versus a placebo in young adults diagnosed with attention deficit hyperactive disorder. 
This study compared 15 non-smoking subjects between the ages of 18-24, diagnosed with ADHD-C, a 
sub-type of ADHD, based on the DSM IV criteria. Prior to each study day, subjects were to abstain from 
taking any prescribed ADHD medication for at least 3 half-lives of the medication, which was verified 
subjectively. Subjects were also required to pass an expired carbon monoxide level of < 10 ppm to 
ensure non-smoking status. Subjects were assessed twice at least 2-10 days apart, by two different 
investigators, once with a 7 mg nicotine patch and once with the placebo patch.19  
Subjects were then admitted to an outpatient clinical research facility, where a 7 mg transdermal 
nicotine patch or an identical appearing placebo patch was administered. Forty-five minutes later the 
patch was removed and each subject immediately continued on to a 4 part, computer based cognitive 
testing session in the following fixed order: 1) stop signal task, 2) the stroop task 3) the choice delay 
task, and 4) high-low imagery task.   
1) The stop signal task tested behavior inhibition by asking subjects to respond to two visual 
“go” signals, the letter X and O and auditory stop signal. The test measures the speed of 
cognitive inhibition that translates to the ability to control a specific impulse.  
2) The stroop task measures the ability of word reading, color naming, and interference. 
Interference measures the brains ability to keep focus with a specific task, while being 
cognitively distracted. In this test subjects are first asked to read a list of colors, ie, BLUE, RED, 
GREEN, written in black ink. The second task asked the subjects to read a list of colors BLUE, 
RED, GREEN, in their respective colored ink. The last task measures the speed at which the 
subject is able to read a list of colors, written in a colored ink different from the color of the 
word, eg, the word BLUE written in green ink. The times between the three tasks are then 
compared.  
3) The choice delay task test analyzes the subject’s ability to wait for a greater delayed reward. 
This task is performed by choosing between 2 arbitrary shapes, a circle or a square. Picking the 
circle gives the participant 5 points, picking the square credits the participant 15-points, but the 
circle is on a continuous 5-second delay and the square is on a variable delay, becoming 
increasingly longer if the subject continues to pick the square.  
4) The high–low imagery task measures recognition memory. Subjects are presented with 14 
words, 7 of high imagery (“Cat”) and 7 of low imagery (“idea”). The subjects are then presented 
with 28 words, the previous 14 high and low imagery words and 14 distracting words. They are 
informed to indicated if the word was from the first 14 original words or a new word to the set. 
Following the cognitive testing, participants completed 3 self-report questionnaires: 1) profile of mood 
states, 2) visual analog battery, and 3) a physical symptom checklist. Clinical investigators also 
completed clinical global impression scores and visual analog battery scores for each participant 
following the completion of the cognitive task sessions. Each task and questionnaire coincided to a 
tangible score that was inputted into Microsoft Excel spreadsheets. Three subjects were excluded from 
the study due to side effects and, therefore, the data of only 12 subjects was compared.19 
This study reported a statistically significant improvement in stop signal reaction time in the 
nicotine patch treatment group compared to the placebo group, showing an improvement in impulse 
control. Potter and Newhouse also reported the nicotine group to be associated with an increase in the 
number of delayed choices during the choice delay task. During the high-low imagery task, the nicotine 
treatment group showed an increase in the number of words correctly identified, suggesting a strong 
influence on acute learning. The subjective and objective questionnaires did not reveal any significant 
drug related changes in comparison to the placebo group.19  
Potter and Newhouse noted multiple limitations to their study. One limitation that was addressed 
included how using a specific ADHD subtype made the results of the study hard to predict for other 
ADHD types. Another limitation mentioned was the possibility that nicotine receptors had been affected 
by previous exposure to stimulants. Participants in the study already taking stimulants were informed to 
allow for the clearing of 3 half lives of the medication before participating in the study. Potter and 
Newhouse addressed the uncertainty of a known connection between nicotinic receptor expressions in 
the presence of previously taken chronic stimulants, and therefore it is uncertain if similar effects would 
occur in subjects without a prior stimulant history.19 
Another limitation mentioned in the study was the fixed order of cognitive testing. The nicotine 
patch was administered for 45 minutes and then removed prior to the cognitive testing session in order 
to minimize the side effects of the nicotine. Therefore, the researchers mentioned nicotine plasma 
concentration could be assumed higher at the start of the testing, but there was no evidence to suggest a 
linear dose response. Potter and Newhouse suggest further studies should investigate for a possible 
relationship between plasma nicotine levels and cognitive functioning.19 
DISCUSSION 
 The results from both18,19 articles demonstrated benefits of nicotine administration in children, 
adolescents and young adults with ADHD. Acute nicotine administration via transdermal nicotine 
patches in young adults with ADHD showed improvements in subjective symptomology, impulse 
control, and cognitive learning. The studies compared were both pilot studies and therefore had very 
small sample sizes. The Shytle el al. study18 had a sample size of 10 and the Potter and Newhouse 
study19 had a sample size of 15. Future larger randomized control trials using transdermal nicotine 
administration would allow for more accurate and convincing results.  
Another limitation of the Shytle et al study18 was the high percentages of side effects, which 
increased the risk of unblinding participants and researchers. Eighty percent of the subjects in the 
treatment group reported nausea as a side effect to the medication, 60% reported stomachaches, 40% 
dizziness, and 40% headaches. The frequency and duration of each side effect was also not reported in 
the overall study, and side effects were reported as a subjective binary (yes or no). Subjects were also 
informed to remove the patch if symptoms of nausea or dizziness occurred, which resulted in 4 out of 5 
participants without a patch for at least 1 day and possibly 2 days. This lack of information could have 
altered the overall application time frame and therefore showed a more acute impact on ADHD 
symptoms, which coincides with other more recent studies, such as the Potter and Newhouse study.19 
One of the greatest limitations to the Potter and Newhouse study,19 as mentioned previously, was 
the overall sample size. Another limitation with the sample population was the lack of demographic 
information collected. The subject’s age and gender was recorded but not compared, and ethnic 
background demographics were not assessed. These limitations could make it difficult to extend the 
study’s findings to a population with diverse demographics, or to evaluate if the results of the study 
might be confounded by significant differences based on gender or race. 
Secondly, as mentioned by Potter and Newhouse19, the study design followed a very regimented 
order. The 4-part cognitive testing session was performed with the stop signal reaction test first, which 
was the only overall task that showed statistically significant improvements. Potter and Newhouse18 
addressed the possibility that nicotine concentrations at the beginning of the cognitive testing sessions 
could have been higher. They suggested future studies should evaluate for a possible dose response in 
relation to cognitive deficits. If the cognitive testing order was randomized, it may have reduced a 
possibility of a nicotine dose response making the overall results of the study stronger.  
The greatest and most daunting risks associated with using nicotine to treat ADHD, especially in 
children and adolescents, are the overall side effects profile, addiction, and cardiovascular risk. 
However, previous studies13,15 have suggested that transdermal application of nicotine should be 
considered safe in the acute setting. Although some researchers believe short-term transdermal nicotine 
administration to be safe, long term or chronic use of transdermal nicotine has not been fully researched. 
Therefore further studies should continue to investigate the safety and efficacy of transdermal nicotine in 
children and adolescents with ADHD. Other research is currently investigating drugs that stimulate the 
nicotinic receptor, or nicotine agonist, that provide similar therapeutic benefits but without the overall 
side effects, addiction, and cardiovascular risk profile. 
Current treatment modalities for children and adolescents with ADHD have been found to 
improve academic productivity equating to better grades, but standardized test scores remain 
unchanged.3 If an acute dose of nicotine could improve the cognitive deficits, impulse control, and 
learning problems associated with those diagnosed with ADHD, there could be a benefit to using 
nicotine administration to help academic performance and possibly improved standardized test scores in 
those with ADHD. Further research should continue to investigate if improvements in cognitive function 
translate to improvements in academic performance and standardized test scores. 
 Shytle et al18 and Potter and Newhouse19 suggested that stimulating the nicotinic cholinergic 
system with nicotine helps to decrease cognitive deficits in those with ADHD and should continue to be 
explored as a viable treatment modality in the future. Newer research has targeted stimulation of the 
nicotinic cholinergic receptors to help reduce symptoms and improve cognitive functioning but without 
the side effects and cardiovascular risks. 
CONCLUSION 
 Based on the studies assessed, transdermal nicotine application in adolescents and young adults 
with ADHD improved symptomatic deficits in learning, recognition memory, delayed gratification, and 
impulse control in an acute setting. However, the overall quality of evidence is very low mainly due to 
small sample sizes. At this point in time, new larger randomized control trials are needed to assess if 
transdermal nicotine administration could be a viable and safe alternative to current treatment 
modalities. Currently there is not enough research using transdermal nicotine on children, adolescents, 
and young adults with ADHD to suggest clinical use, but research has been directed to activate 
stimulation of the nicotinic cholinergic receptor to help improve cognitive deficits linked with ADHD 
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Limitations  Indirectness 





Shytle et al RCT  Serious a, b, Not Serious  Not Serious Serious c Unlikely  None Very Low  
Potter and 
Newhouse 
RCT Not Serious  Not Serious  Not Serious  Serious c Unlikely None Low 
aRisk of unblinding due to a high percentage of side effects in treatment group 
b Subjective outcome 
c  Small sample size  
 
 
 
 
 
 
 
